Zenith Epigenetics’ experienced research team has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET inhibitors. Our experienced management team and world-leading clinical collaborators are developing BETi combination therapies for multiple oncology indications. With a strong emphasis on translational medicine – for selecting patients that will benefit most from the therapy – Zenith is a leader in innovative clinical development of epigenetic combination therapies.
Our lead BETi, ZEN-3694, is in Phase 2 clinical development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer.
Zenith Capital Corp. held its Annual Meeting of the Shareholders on Thursday, October 27, 2022.
The meeting included a presentation from President & CEO Donald McCaffrey. You can find a recording of the management presentation HERE
On July 15, 2021, Zenith presented at the Epigenetic Therapeutic Targets digital event
"Clinical Development of The BET Bromodomain Inhibitor ZEN-3694 In Solid Tumors: Lessons Learned"
• Design of epigenetic combinatorial therapies
• Clinical activity in breast and prostate cancer patients
• Mechanisms of action: similarities and differences between the prostate
and breast cancer trials
On June 1, 2021, Zenith presented at the OICR Jlabs Cancer Symposium with regards to the clinical development of the BET bromodomain inhibitor ZEN-3694 in multiple oncology indications.
